Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Dec 12, 2011)
  • 8-K (Nov 10, 2011)
  • 8-K (Oct 28, 2011)
  • 8-K (Oct 25, 2011)
  • 8-K (Aug 10, 2011)
  • 8-K (Jul 27, 2011)

 
Other

Adolor 8-K 2009

Documents found in this filing:

  1. 8-K
  2. 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)  January 30, 2009

 

Adolor Corporation

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-30039

 

31-1429198

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer

of incorporation)

 

 

 

Identification No.)

 

 

 

 

 

700 Pennsylvania Drive, Exton, PA

 

19341

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (484) 595-1500

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 1.01                                             Entry into a Material Definitive Agreement

 

On January 30, 2009, Adolor Corporation (the “Company”) and Glaxo Group Limited (“Glaxo”) entered into Amendment No. 4 (“Amendment No. 4”) to Collaboration Agreement, as previously amended (the Collaboration Agreement”).  Under Amendment No. 4, the Company and Glaxo, effective as of January 1, 2009, modified certain provisions of the Collaboration Agreement (i) to reflect the current plan jointly developed by the parties relating to the sale and promotion of ENTEREG® (alvimopan) and (ii) to modify certain payment provisions of the Collaboration Agreement, principally including the acceleration of payments owed by Glaxo to the Company.  These payments are expected to total approximately $9 million and will be received by the Company in the first half of 2009.

 

The foregoing is a summary of the material terms of Amendment No. 4 and does not purport to be complete.

 

There are no material relationships between Glaxo and the Company or any of the Company’s affiliates, directors or officers (or any associate of any such director or officer), other than by virtue of Amendment No. 4, the Collaboration Agreement and the Distribution Services Agreement dated June 29, 2004 by and between the Company and an affiliate of Glaxo.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

 

ADOLOR CORPORATION

 

 

 

 

 

 

 

By

/s/ John M. Limongelli

 

Name:

John M. Limongelli

 

Title:

Sr. Vice President, General Counsel and Secretary

 

 

Dated:  February 5, 2009

 

3


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki